GLP-1 Medications May Quiet 'Drug Noise' Across All Addictions, Study Suggests

Medications originally designed to manage diabetes and obesity may hold promise as a broad-spectrum treatment for addiction—one that works across alcohol, opioids, cocaine, nicotine, and other substances by targeting craving itself, according to a large-scale analysis of more than 600,000 U.S. veterans published Wednesday in The BMJ.

Researchers at Washington University School of Medicine in St. Louis examined electronic health records of patients with type 2 diabetes who were treated with GLP-1 receptor agonists—including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, and dulaglutide—compared to those who received a different class of diabetes medication. The findings suggest these drugs may offer a fundamentally different approach to addiction treatment: not addressing one substance at a time, but quieting what lead researcher Dr. Ziyad Al-Aly calls "drug noise"—the relentless craving that drives compulsive use.

"In addiction medicine, a lot of treatments target just one thing—for example, a nicotine patch helps with smoking, but not alcohol," said Al-Aly, a clinical epidemiologist and chief of the Research and Development Service at the VA Saint Louis Health Care System. "The revelation about GLP-1 medication is that it really works against all major substances, and it works uniformly, not because it acts against alcohol or opioids or nicotine specifically, but because it is likely acting against the craving itself."

Prevention and Treatment Effects

The study tracked 606,434 veterans over three years, dividing them into two groups: those without pre-existing substance use disorder and those who already had a diagnosis. Among participants without prior substance use disorder, GLP-1 use was associated with a 14% reduced risk of developing any substance use disorder during the study period—translating to seven fewer new diagnoses per 1,000 GLP-1 users.

The protective effect varied by substance:

• Alcohol use disorder: 18% risk reduction
• Cannabis use disorder: 14% reduction
• Cocaine use disorder: 20% reduction
• Nicotine use disorder: 20% reduction
• Opioid use disorder: 25% reduction

For patients already diagnosed with substance use disorder, GLP-1s were tied to dramatic reductions in serious harms. Compared to those taking non-GLP-1 diabetes medications, GLP-1 users experienced:

• 30% fewer emergency department visits
• 25% fewer hospitalizations
• 40% fewer overdoses
• 50% fewer drug-related deaths

This amounted to 12 fewer serious harm events per 1,000 GLP-1 users over three years.

"We're talking about a diabetes and obesity drug; we're not talking about an addiction drug here," Al-Aly said. "What's surprising is the breadth and consistency of effect across all of these different substances."

A Common Biology of Craving

The cross-substance signal points toward a shared biological pathway underlying addiction. GLP-1 receptors exist in brain regions that modulate reward processing, and the medications may work by blunting the neural drive toward whatever substance a person is drawn to—whether that's food, alcohol, or methamphetamine.

Patients taking GLP-1s for weight loss often describe a quieting of "food noise," the persistent mental preoccupation with eating that fuels overeating. Al-Aly's team hypothesizes a similar mechanism may apply to addiction more broadly: the drugs dampen the intrusive thoughts, urges, and emotional pull that keep someone locked in a cycle of use.

That uniformity of effect is significant in a field where medication options are limited and substance-specific. For opioid use disorder, medications like buprenorphine and methadone exist. Alcohol use disorder has naltrexone and acamprosate. But for stimulants like methamphetamine or cocaine, there is no FDA-approved medication at all. GLP-1s, if validated in randomized controlled trials, could fill gaps across the addiction treatment landscape.

Clinical Trials on the Horizon

Though observational studies like this one can identify associations, they cannot prove causation. Factors such as greater patient engagement, more intensive clinical follow-up, or healthier baseline behaviors among GLP-1 users could partially explain the findings. Dr. Caleb Alexander, a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health who was not involved in the study, noted that the 50% reduction in overdose deaths "appeared too large to be believable" without further validation, though he praised the study's strengths.

"It's a large and thoughtfully conducted observational study," Alexander said. "The key concern is that people who start GLP-1 medications may differ in important ways from people starting other diabetes drugs."

That's why researchers are calling for randomized controlled trials—the gold standard for testing safety and efficacy. Several are now underway or in planning stages, including trials testing semaglutide for alcohol use disorder at Oklahoma State University and the National Institute on Drug Abuse, and studies examining effects on cocaine and opioid use disorders. Novo Nordisk, maker of Ozempic and Wegovy, has announced plans to study alcohol consumption in patients with alcohol-related liver disease, and Eli Lilly is testing an experimental GLP-1-class drug called brenipatide on alcohol, tobacco, and opioid use disorders.

Dr. W. Kyle Simmons, a professor of pharmacology and physiology at Oklahoma State who is leading one of the alcohol trials, said results from well-designed studies could arrive within six months. "If these drugs turn out to be safe and efficacious for treatment of substance-use disorder, because they are so broadly used for other reasons in our society, they would just automatically, de facto, become the most widely prescribed pharmacotherapy for addiction."

Population-Level Impact

With millions of Americans already using GLP-1 medications—an estimated one in eight adults, according to a KFF survey—any protective effect against substance use disorders could have broad public health implications, particularly as the U.S. continues to grapple with an overdose crisis that claimed more than 79,000 lives in 2024, according to the CDC.

Though drug overdose death rates have been declining, researchers attribute that trajectory to a combination of factors: changes in the illicit drug supply, expanded access to medications for opioid use disorder, and wider distribution of naloxone, the opioid overdose reversal medication. Whether widespread GLP-1 use is also contributing to the decline is difficult to determine from observational data alone, Al-Aly cautioned.

The study also found a 25% reduction in suicidal ideation among GLP-1 users, adding to a growing body of evidence that the medications do not increase suicide risk—a concern that prompted a European regulatory investigation in 2023 but was not supported by subsequent large-scale studies.

Unanswered Questions

Key questions remain. What happens if someone stops taking a GLP-1? Does tolerance develop over years, reducing effectiveness? Could dampening reward circuitry affect everyday experiences of pleasure, motivation, or healthy risk-taking?

"I think we have to be cautious here," Al-Aly said. "We don't know what we don't know about these drugs."

But if randomized trials confirm the findings, GLP-1s could represent a paradigm shift in addiction medicine: a single medication targeting the common neural substrate of craving rather than the pharmacology of individual substances. For clinicians, it could mean treating patients with obesity or diabetes who also struggle with alcohol, nicotine, or opioid use disorder with one prescription. For patients, it could mean relief from the "drug noise" that makes recovery feel impossible.

"Moving beyond food noise to drug noise," Al-Aly said, "GLP-1s are quieting the roar of addiction."